177 related articles for article (PubMed ID: 38772115)
1. The mechanistic view of non-coding RNAs as a regulator of inflammatory pathogenesis of Parkinson's disease.
Li Y; Yu C; Jiang X; Fu J; Sun N; Zhang D
Pathol Res Pract; 2024 Jun; 258():155349. PubMed ID: 38772115
[TBL] [Abstract][Full Text] [Related]
2. Non-coding RNAs: The key regulators in NLRP3 inflammasome-mediated inflammatory diseases.
Feng X; Luo D; Wei G; Zhan F; Hua F; Xu G
Int Immunopharmacol; 2021 Nov; 100():108105. PubMed ID: 34481143
[TBL] [Abstract][Full Text] [Related]
3. RND3 modulates microglial polarization and alleviates neuroinflammation in Parkinson's disease by suppressing NLRP3 inflammasome activation.
Hu W; Wang M; Sun G; Zhang L; Lu H
Exp Cell Res; 2024 Jun; 439(1):114088. PubMed ID: 38744409
[TBL] [Abstract][Full Text] [Related]
4. Autophagy-associated non-coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis.
Hussain MS; Moglad E; Afzal M; Sharma S; Gupta G; Sivaprasad GV; Deorari M; Almalki WH; Kazmi I; Alzarea SI; Shahwan M; Pant K; Ali H; Singh SK; Dua K; Subramaniyan V
CNS Neurosci Ther; 2024 May; 30(5):e14763. PubMed ID: 38790149
[TBL] [Abstract][Full Text] [Related]
5. Long Noncoding RNA SNHG1 Promotes Neuroinflammation in Parkinson's Disease via Regulating miR-7/NLRP3 Pathway.
Cao B; Wang T; Qu Q; Kang T; Yang Q
Neuroscience; 2018 Sep; 388():118-127. PubMed ID: 30031125
[TBL] [Abstract][Full Text] [Related]
6. NF-κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective.
Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Jabir MS; Saad HM; Batiha GE
J Cell Mol Med; 2023 Jul; 27(13):1775-1789. PubMed ID: 37210624
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3.
Li D; Yang H; Ma J; Luo S; Chen S; Gu Q
Hum Cell; 2018 Apr; 31(2):106-115. PubMed ID: 29274035
[TBL] [Abstract][Full Text] [Related]
8. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease.
Chen J; Mao K; Yu H; Wen Y; She H; Zhang H; Liu L; Li M; Li W; Zou F
J Neuroinflammation; 2021 Dec; 18(1):295. PubMed ID: 34930303
[TBL] [Abstract][Full Text] [Related]
9. The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson's disease via the microglial NLRP3 inflammasome.
Kou L; Chi X; Sun Y; Han C; Wan F; Hu J; Yin S; Wu J; Li Y; Zhou Q; Zou W; Xiong N; Huang J; Xia Y; Wang T
J Neuroinflammation; 2022 Jun; 19(1):133. PubMed ID: 35668454
[TBL] [Abstract][Full Text] [Related]
10. Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease.
Han X; Sun S; Sun Y; Song Q; Zhu J; Song N; Chen M; Sun T; Xia M; Ding J; Lu M; Yao H; Hu G
Autophagy; 2019 Nov; 15(11):1860-1881. PubMed ID: 30966861
[TBL] [Abstract][Full Text] [Related]
11. miR-29c-3p inhibits microglial NLRP3 inflammasome activation by targeting NFAT5 in Parkinson's disease.
Wang R; Li Q; He Y; Yang Y; Ma Q; Li C
Genes Cells; 2020 Jun; 25(6):364-374. PubMed ID: 32160394
[TBL] [Abstract][Full Text] [Related]
12. Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease.
Li Y; Xia Y; Yin S; Wan F; Hu J; Kou L; Sun Y; Wu J; Zhou Q; Huang J; Xiong N; Wang T
Front Immunol; 2021; 12():719807. PubMed ID: 34691027
[TBL] [Abstract][Full Text] [Related]
13. The roles of non-coding RNAs in Parkinson's disease.
Majidinia M; Mihanfar A; Rahbarghazi R; Nourazarian A; Bagca B; Avci ÇB
Mol Biol Rep; 2016 Nov; 43(11):1193-1204. PubMed ID: 27492082
[TBL] [Abstract][Full Text] [Related]
14. NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson's Disease.
Han QQ; Le W
Neurosci Bull; 2023 May; 39(5):832-844. PubMed ID: 36757612
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA GAS5 promotes microglial inflammatory response in Parkinson's disease by regulating NLRP3 pathway through sponging miR-223-3p.
Xu W; Zhang L; Geng Y; Liu Y; Zhang N
Int Immunopharmacol; 2020 Aug; 85():106614. PubMed ID: 32470877
[TBL] [Abstract][Full Text] [Related]
16. Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease.
Grotemeyer A; Fischer JF; Koprich JB; Brotchie JM; Blum R; Volkmann J; Ip CW
J Neuroinflammation; 2023 Mar; 20(1):79. PubMed ID: 36945016
[TBL] [Abstract][Full Text] [Related]
17. NLRP3 inflammasome pathway in atherosclerosis: Focusing on the therapeutic potential of non-coding RNAs.
Al-Hawary SIS; Jasim SA; Romero-Parra RM; Bustani GS; Hjazi A; Alghamdi MI; Kareem AK; Alwaily ER; Zabibah RS; Gupta J; Mahmoudi R; Hosseini-Fard S
Pathol Res Pract; 2023 Jun; 246():154490. PubMed ID: 37141699
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease.
Zhou Y; Lu M; Du RH; Qiao C; Jiang CY; Zhang KZ; Ding JH; Hu G
Mol Neurodegener; 2016 Apr; 11():28. PubMed ID: 27084336
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the role of non-coding RNAs in the pathophysiology of Parkinson's disease.
Rezaei O; Nateghinia S; Estiar MA; Taheri M; Ghafouri-Fard S
Eur J Pharmacol; 2021 Apr; 896():173914. PubMed ID: 33508286
[TBL] [Abstract][Full Text] [Related]
20. Asiaticoside exerts neuroprotection through targeting NLRP3 inflammasome activation.
He Z; Hu Y; Zhang Y; Xie J; Niu Z; Yang G; Zhang J; Zhao Z; Wei S; Wu H; Hu W
Phytomedicine; 2024 May; 127():155494. PubMed ID: 38471370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
